Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 3762179, 3 pages
https://doi.org/10.1155/2017/3762179
Research Article

Possible Effect of Concomitant Prokinetics and Herbal Medicines against Nausea in Patients Taking Lubiprostone

Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan

Correspondence should be addressed to Takatsugu Yamamoto; pj.ca.u-oykiet.dem@tmmy

Received 27 August 2017; Accepted 26 September 2017; Published 7 December 2017

Academic Editor: Toshimi Chiba

Copyright © 2017 Takatsugu Yamamoto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. V. Roque and E. P. Bouras, “Epidemiology and management of chronic constipation in elderly patients,” Clinical Interventions in Aging, vol. 10, pp. 919–930, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. D. A. Drossman, W. D. Chey, J. F. Johanson et al., “Clinical trial: Lubiprostone in patients with constipation-associated irritable bowel syndrome - Results of two randomized, placebo-controlled studies,” Alimentary Pharmacology & Therapeutics, vol. 29, no. 3, pp. 329–341, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. F. Johanson, D. A. Drossman, R. Panas, A. Wahle, and R. Ueno, “Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation,” Alimentary Pharmacology & Therapeutics, vol. 27, no. 8, pp. 685–696, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. F. Johanson, D. Morton, J. Geenen, and R. Ueno, “Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation,” American Journal of Gastroenterology, vol. 103, no. 1, pp. 170–177, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. C. F. Barish, D. Drossman, J. F. Johanson, and R. Ueno, “Efficacy and safety of lubiprostone in patients with chronic constipation,” Digestive Diseases and Sciences, vol. 55, no. 4, pp. 1090–1097, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Camilleri, A. E. Bharucha, R. Ueno et al., “Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 290, no. 5, pp. G942–G947, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Matsuura, M. Inamori, H. Endo et al., “Lubiprostone decreases the small bowel transit time by capsule endoscopy: an exploratory, randomised, double-blind, placebo-controlled 3-way crossover study,” Gastroenterology Research and Practice, vol. 2014, Article ID 879595, 6 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. G. F. Longstreth, W. G. Thompson, W. D. Chey, L. A. Houghton, F. Mearin, and R. C. Spiller, “Functional bowel disorders,” Gastroenterology, vol. 130, no. 5, pp. 1480–1491, 2006. View at Publisher · View at Google Scholar
  9. B. Gras-Miralles and F. Cremonini, “A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly,” Clinical Interventions in Aging, vol. 8, pp. 191–200, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Abe, Y. Hachiro, Y. Ebisawa, H. Hishiyama, M. Murakami, and M. Kunimoto, “Efficacy of itopride in the prevention of lubiprostone-induced nausea,” Open Journal of Gastroenterology, vol. 04, no. 09, pp. 305–309, 2014. View at Publisher · View at Google Scholar
  11. M. Yuki, Y. Komazawa, Y. Kobayashi et al., “Effects of Daikenchuto on Abdominal Bloating Accompanied by Chronic Constipation: A Prospective, Single-Center Randomized Open Trial,” Current Therapeutic Research - Clinical and Experimental, vol. 77, pp. 58–62, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Hasebe, N. Ueno, M. W. Musch et al., “Daikenchuto (TU-100) shapes gut microbiota architecture and increases the production of ginsenoside metabolite compound K,” Pharmacology Research & Perspectives, vol. 4, no. 1, Article ID e00215, 2016. View at Publisher · View at Google Scholar
  13. K. Togawa, J. Matsuzaki, M. Kobayakawa et al., “Association of baseline plasma des-acyl ghrelin level with the response to rikkunshito in patients with functional dyspepsia,” Journal of Gastroenterology and Hepatology, vol. 31, no. 2, pp. 334–341, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Saegusa, T. Hattori, M. Nahata, C. Yamada, and H. Takeda, “A new strategy using rikkunshito to treat anorexia and gastrointestinal dysfunction,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 364260, 10 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. O. J. Kwon, M. Y. Kim, S. H. Shin et al., “Antioxidant and anti-inflammatory effects of rhei rhizoma and coptidis rhizoma mixture on reflux esophagitis in rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 2052180, 13 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus